You Are Here » Home » Investor Information » Press Releases

DECN Press Releases


Go to: 2020 - 2019 - 2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009 - 2008 - 2007 - 2006 - 2005

2020

December 2020

  • DECN to Announce Various Testing Results This Week for Its COVID-19 GenViro! Swift Kit (December 21)

  • DECN Comments on Recent Legal Filings by Federal Agencies (December 18)

  • DECN Provides Testing Update for US, Korea and XPRIZE With Plans for Walk-in Donor Study for at-Home GenViro! Saliva Swift :10 Test Kit (December 16)

  • DECN Secures Exclusive Distributor Agreement With a German Based Company for the Distribution of Genviro! Covid-19 :10 Saliva Testing Kits and Meters in 18 EU Countries, Norway and the UK (December 10)

  • DECN Announces Significant Agreement With Russian Federation Partner for Genviro! and Genviro! Pro COVID-19 Testing Kits as Well as Its Venerable GenUltimate! Blood Glucose Products (December 1)

    • November 2020

  • DECN XPRIZE Testing Data for Rapid COVID-19 Testing Technology Yields Near Textbook Results (November 23)

  • DECN GenViro! Trial Using Human Saliva Donors for Its Swift Test Kits Proceeds Directly to FDA Level Testing As COVID-19 Product Testing Enters “Home Stretch” (November 12)

  • DECN Continues to Add GenViro! Dealers With an Agreement Covering Puerto Rico, the Dominican Republic, the US Virgin Islands and Geographies Across the Caribbean and Central America (November 6)

  • DECN Announces Additional Distribution Agreement With a Distributor and Dealers in Nigeria, Ivory Coast and Lebanon (November 3)

    • October 2020

  • DECN Announces Commencement of US-Based Donor Study for FDA EUA Guidance Testing for Their 10.5 Second Genviro! Saliva Swift COVID-19 Test Kits (October 19)

  • DECN Provides Progress Update on Major Events for Its GenViro! Saliva Swift Kits for the Detection of COVID-19 (October 13)

  • DECN Enters into a New 6 Month $300,000 Promissory Note with Major Current Investor to Help Fund the Recent International Launch if its GenViro! Swift Kits (October 5)

  • DECN Receives Significant Initial Order for International GenViro! Saliva Swift Kits for the Detection of COVID-19 (October 2)

    • September 2020

  • DECN Signs Agreement With US-Based Laboratory as Testing Partner for Genviro! Saliva Swift Kit Testing for Additional FDA, EU CE Mark and Russian Federation Submissions (September 30)

  • DECN Announces Completion of Critical Instructional Videos for its GenViro! Saliva Swift Kit for USA and International Professional Use (September 22)

  • DECN Announces Finalizing of International Genviro! COVID-19 Saliva Swift Kits for Global Market and Establishes Introductory Sales Pricing (September 18)

  • DECN Enters into an Additional 6 Month $300,000 Promissory Note With Major Current Investor to Further Assist Launch of Genviro Swift Kits for the Detection of the Covid-19 Virus (September 15)

  • DECN to Launch Its International Version GenViro! Saliva Swift :10.5 Second Covid-19 Kits on September 26, Will Then Accept Orders from Its Asian Distributor (September 1)

    • August 2020

  • DECN Provides Update on Accomplishments and Pathway to Securing FDA EUA Approval for its COVID-19 "Transmission Indicating Testing" Methodology (August 26)

  • DECN CEO Releases Open Letter on FDA At-Home COVID-19 Rapid Testing Guidelines Saying It's the Speed to Results Reporting and Certain Added Regulations That Need to Be Addressed (August 10)

  • DECN Publicly Disavows Covid-19 Swift Kit Video as Produced by Outside Unauthorized Party (August 7)

  • DECN Issues Support for Recently Announced FDA COVID-19 At-Home Testing Template as the Company's Submission for Its Genviro! Swift COVID-19 At-Home Test Kit Anticipated Many of the New FDA Requisites (August 3)

    • July 2020

  • DECN Readies its GenViro! Covid-19 Swift Kits for Latest FDA Mandated Testing of both Saliva and Blood Protocols as it Enters Final Selection Process for a U.S. Based Testing Partner (July 23)

  • DECN Says its Newest GenViro! COVID-19 Swift Kit Saliva Testing Option Can Play an Extensive Role in the Re-Opening of Schools as Company Awaits FDA Authorization (July 17)

  • DECN to add GenViro! Saliva Covid-19 Swift Kit :10.5 for Professional and Home Use Testing, Providing an Alternative Modality to its Finger Stick Methodology (July 10)

  • DECN Announces Distribution Agreement Covering GenViro! Covid-19:10.5 Swift Kits and Its GenUltimate and TGB Products in India, Malaysia, Sri Lanka, Singapore, Indonesia, Thailand, Vietnam, Nepal, Bangladesh and Australia (July 8)

  • DECN CEO Offers Open Letter on COVID-19 Testing Highlighting Needed Support for Innovation in Testing (July 2)

    • June 2020

  • DECN Files Provisional Patent For GenViro! Professional COVID-19 :15 Swift Kit, Adds Enhanced Technology To Allow For Even Swifter Results (June 17)

  • DECN Readies Its 2nd EUA Amendment With The FDA For Its GenViro! Swift Professional COVID-19 :15 Test Kit, And Also Announces Its Further Support For More And Continued Worldwide COVID-19 Testing (June 12)

  • DECN CEO Interviewed On Vancouver's #1 News/Talk Radio Station, Discusses GenViro! Covid-19 :15 Swift Test Kit, Additional Interviews Anticipated (June 4)

    • May 2020

  • DECN to Publish Specific Testing Completed on its GenViro! Covid-19 :15 Swift Test Kits for Viewing by Shareholders and Other Interested Parties (May 21)

  • Covid-19:15 Second Home Testing GenViro! Swift Kit Identified By Largest CBS Affiliate In The Country As Potential Testing Solution To Help Get Country Back To Work (May 12)

    • April 2020

  • DECN Strongly Questions SEC’s Unilateral Imposition Of 10-Day Trading Suspension -- Company Is Undaunted And Still Seeks Expedited FDA EUA Approval For Genviro! Swift :15 Virus Test Kit (April 27)

  • DECN To Submit Second EUA Application For Covid-19 :15 Home Testing GenViro! Swift Kit, Reports Huge Response From Fortune 500 Companies (April 23)

  • DECN to Provide Updates on the Progress of Our GenViro! Covid-19 Test Kits on Thursday April 23 (April 21)

  • DECN Receives Pre-EUA Acknowledgement Letter And Product Serial Number From U.S. FDA For GenViro!(TM) Covid-19 Screening Kit For Professional Use (April 7)

  • DECN Files Finalized FDA EUA Application for Its Genviro! Covid-19 Swift Kit, Receives Notification of Acceptance From FDA After-Hours on Friday 4/3/2020 (April 6)

    • March 2020

  • DECN to Add 2nd Covid-19 Test Kit Using Antibody/Antigen Methodology as a Determination Test for Patients Who Previously Tested Positive for Covid-19 (March 25)

  • DECN Finalizes FDA Pre-EUA Version of Its Genviro! Screening Covid-19 Swift Kit, Providing Results in 15 Seconds Using Only 1.0-2.0 Microliters Whole Blood (March 23)

  • DECN to Finance 2Q 2020 Roll Out of its GenViro! Covid-19 "Rapid" Kits Using Non-Dilutive Debt Financing Totaling $13 Million Acquired in Near 0% Rate Environment (March 20)

  • DECN's GenViro!(TM) COVID-19 "Rapid" Kit to Reap Huge Boost from 3/16 FDA Guidance Allowing for Near Immediate Distribution of Kits Prior to Emergency Waiver Grant (March 18)

  • DECN'S GenViro!(TM) Corona Virus "Swift" Kit, Now to Be Additionally Offered to Commercial Labs and Religious Groups as 12 Month Forecast is Raised to 525MM (March 17)

  • DECN Updates on Its Corona Virus Testing Product Genviro!(TM), With 200,000 Kits to Be Provided in USA & EU Prior to the Summer, 12 Month Forecast Updated to 480mm (March 16)

  • DECN Provides First Looks At Its GenViro(TM) Corona Virus Screening Kit & First Year Product Forecast of 420 Million Kits, with Sales Beginning Late 3Q 2020 (March 11)

  • DECN Fills in the Gaps, Adds to Knowledge Base for its GenViro(TM) Coronavirus (Covid19) Multi-Dimensional Diagnostic Methodology Announced March 2 (March 4)

  • DECN Jumps into Screening and Testing Channel For Coronavirus (COVID19) Using Its Innovative Impedance Technology First Implemented In Its GenUltimate TBG (March 3)

    • February 2020

  • DECN Announces Market Readiness of Its GenUltimate TBG, Adds To Product's Compatibility at The Request Of Strategic Partner, Completes Its Universal Translator GenExpidient! Device (February 20)

  • DECN Updates on Major 2020 Business Events, Announces New Large Retailer Arrangements, as Company Marches Forward (February 4)

    • January 2020

  • DECN adds to Domestic and International Channels for its GenAccord! Product, Inclusive of the EU and Russian Federation, as Company also Schedules Entry of 2nd GenAccord! Product for Multi-Patient Use (January 21)

    • (Return to Top)

    2019

    December 2019

  • DECN in Major Revenue Move Decides to Include New GenAccord! Product Line in its Upcoming Strategic Agreement at the Request of Strategic Partner (December 12)

  • DECN to Immediately Take Control of Two Market Ready, FDA Cleared, Glucose Monitoring Systems to Augment Its Primary Marketplace Positions (December 10)

    • November 2019

  • DECN Completes Its Genultimate! TBG System Meters, Adding to Final Brilliance After Receiving Development Consultation From Licensors and Big Box (November 7)

    • October 2019

  • DECN Enters Exciting New Phase After High Court Hearing, Long Running Legal Battles With Johnson & Johnson Are Nearing A Positive Ending (October 24)

    • September 2019

  • DECN Retains Counsel To File For Two Patents Covering GenUltimate TBG Test Strip And System, Consents To The Publication A White Paper By A Biotech Industry Luminary (September 19)

  • DECN Launches Premier Versions Of Its Successful Genultimate Test Strip, Completes Media Commercial Set To Debut In National Media Markets (September 11)

  • DECN Adds International Distribution for its Genultimate, Genchoice, Genprecis and Gensure Products (September 4)

    • August 2019

  • After Disclosing the Choice of Licensing Partner Last Week, DECN Receives Two New Accretive Propositions for Its Panacea GenUltimate! TBG (August 8)

  • DECN Chooses to License its Genultimate TBG Technology to Perfectly Situated Partner, Anticipates Agreement Will Yield Revenue Stream in Excess of $100 Million Over 5 Year Term, Company to Retain its Intellectual Property (August 1)

    • July 2019

  • DECN's Appeal To Be Heard In Case Against J&J Over A Grossly Unfair Ruling And Lower Court's Termination Of The Case Against Their Court Wounded Adversary (July 18)

    • June 2019

  • DECN in Pact with Mega Pet Products Retailer Fetch for Pets Tripling Market For Company's Petsure Test Strips and Genultimate! 4pets Test Strips and Meters (June 25)

  • DECN Narrows Choices Of Likely Strategic Partners To Two, Serious Talks Begin (June 19)

  • DECN Discusses Current Financings with Aplha Capital Anstalt, Accepts Latest Proposition from Solicited Party, Will Choose from Two Proposals to Bring Closure (June 13)

  • DECN Discusses Propositions Received For Its GenUltimate TBG (June 7)

  • DECN Accepts 4th Unsolicited Proposition for its GenUltimate TGB Product, and Today Launches its GenUltimate TGB Product into Select International Markets (June 6)

    • May 2019

  • DECN to Launch Panacea GenUltimate TBG Diabetic Test Strip and Precise Meter June 6 in Select Off-Shore Markets, with Initial Plan To Target Users And Former Users Of The J&J/Lifescan Meters (May 30)

  • DECN Discusses Marketplace Intrique Surrounding Its Panacea Product Genultimate TBG, As It Readies June 6 Introduction (May 29)

  • DECN to Discuss in Detail Three Major Events Just After Memorial Day Holiday (May 23)

  • DECN Sets Plan to Make Upcoming Patent Infringement Appeal Hearing and Mediation with Johnson & Johnson a Foundation for Substantial Recovery (May 9)

  • DECN's Appeal Nearing Oral Arguments in its Patent Battle with Johnson & Johnson Over the Unjust Ruling in the Nevada Lower Court (May 7)

    • April 2019

  • In Prelude to Probable Transaction DECN Decides to Infuse its Outre' Precise, TBG Technology to its GenChoice Test Strip, Now in FDA 510k Review (April 23)

  • DECN Expands Talks Involving Its GenUltimate TBG System, Balances Potential and Competing Outcomes with Recent Intro to 2nd Interested Party (April 17)

  • DECN Hails Completion of Its Genultimate! TBG Panacea System, 3rd Party Testing to Begin in Next 7 Days, Clinical Trials Testing to Begin in May (April 4)

    • March 2019

  • DECN Launches Its Genultimate 4Pets and Avantage Meter, Ground-Breaking Products for the Testing of Dogs, Cats and Horses, Receives First Retail Orders, Establishes Innovative Rebate Program (March 14)

  • DECN in Pact with Alpha Capital Anstalt (March 14)

  • DECN Enters into Strategic Agreement with Paragon Sales and Marketing Inc. for Big Box Sales to Walmart, CVS, Walgreens, Costco and Cardinal Health (March 12)

    • January 2019

  • DECN Subsidiary Receives 510k Submission And ''K'' Numbers from FDA CDRH for Its Genchoice! Test Strip at the Close of the Government Shutdown (January 30)

  • DECN Discusses Its Panacea GenUltimate! TBG System, Offering Elite Performance And Premier Upgrade Path For 4+ Million Users Of Lifescan Ultra Meters (January 17)


    • (Return to Top)

    2018

    December 2018

  • DECN Subsidiaries Appeal Nevada District Court Trial Judge's Ruling to U.S. Court of Appeals for the Federal Circuit (The Patent Appeals Court) (December 19)

  • DECN Engages Second Korean Manufacturing Partner to Raise Its Factory Capacity by Two Million Boxes of ''GEN'' Test Strips Annually (December 17)

  • DECN Releases its Strategic IP And Product Development Introduction Plan With a Summary of 2018 Achievements and 2019 Expectations (December 11)

    • November 2018

  • DECN CEO Keith M. Berman Is Interviewed By Prestigious Wall Street Reporter Who Describe Company And Products As ''Game Changer'' (November 27)

  • DECN Receives Completed Clinical Trial Data, Charts and Spreadsheets Essential for its Imminent Genchoice! Test Strip (November 6)

    • October 2018

  • DECN Set to Appeal the Clearly Unfair Ruling in Court's Termination of the DECN Patent Infringement and False Advertising Case Battle with Johnson & Johnson (October 30)

    • September 2018

  • DECN Board Of Directors In Final Review Of Preliminary Financing Agreement For $4.75 Million Investment (September 13)

  • DECN Announces Major Step Ahead with Offering Statement (September 6)

    • August 2018

  • DECN Announces Significant Updates For Products And Programs (August 14)

  • DECN Makes Its Mark In $1+ Billion Dollar Pet Diabetes & Glucose Testing Market With Two New Products, Petsure! & Petultimate! (August 7)

    • July 2018

  • Decision Diagnostics Corp. Announces Election of Two Key Managers to the Board of Its Korean Partner "The Bio Co, Ltd." (July 12)

    • April 2018

  • Decision Diagnostics (DECN) Contemplates Additional Legal Actions Against Longtime Adversary Johnson & Johnson (JNJ) (Apr 18)

    • March 2018

  • Decision Diagnostics Discusses Culmination of Patent Case Against J&J and Its Divisions Based on The Federal Doctrine of Equivalents (Mar 27)

  • Decision Diagnostics' Panacea Genprecis! Product Moves into Pre-Production, First Round Clinical Trials to Begin in the Next 30 Days (Mar 21)

  • Decision Diagnostics' Fundamental Genchoice! Diabetic Test Strip Moves into Formal Managed Clinical Trials and Advanced Testing for Upcoming 510k Filing with U.S. FDA (Mar 13)

    • January 2018

  • Decision Diagnostics Announces 2018 Business Focus Through the Introduction of New Products, Positive Conclusion to J&J Litigation, and Hybrid Private Label Business Model (Jan 3)


    • (Return to Top)

    2017

    December 2017

  • Decision Diagnostics Provides Additional Commentary About Its New GenAccord!(TM) Diabetic Test Strip (Dec 20)

  • Decision Diagnostics Announces New GenAccord!(TM), Diabetic Test Strip with First Use of Its GenPrecis!(TM) Full Spread Electrode Technology (Dec 14)

    • November 2017

  • Decision Diagnostics Corp. CEO Offers Primary Update on Legal Proceedings, Potential Outcomes, History, and Synopsis on Its Strategic Suit Against J&J (Nov 1)

    • October 2017

  • Decision Diagnostics Corp. Further Discusses Its Panacea GenPrecis!(TM) Product Just Released into Advanced Development (Oct 18)

  • Decision Diagnostics Announces Completion of Feasibility Testing for Their Inspired Genpresis!(TM) Precision Diabetes Glucose Testing System! (Oct 12)

  • Decision Diagnostics Announces the Completion of Development and the Onset of Clinical Trials for Its Fundamental Genchoice!(TM) Diabetic Test Strip (Oct 10)

    • September 2017

  • Patent Litigation Brought by Decision Diagnostics Subsidiaries against Johnson & Johnson/Lifescan Moves Toward Major Ruling (Sep 21)

  • Decision Diagnostics Announces the Launch of Its Essential New Gensure!(TM) Diabetic Test Strip for Developing World Markets (Sep 13)

  • Decision Diagnostics in Receipt of Revised Cash Offer from Proposed M&A Partner, Enhanced by 21% Over Previously Disclosed Proposals (Sep 7)

    • August 2017

  • DECN Subsidiaries Plan Rebuttal Brief for Aug. 28th to Debunk J&J/Lifescan's Flawed Legal Reasoning and Factual Misrepresentations in Patent Case (Aug 24)

  • Decision Diagnostics Board Reacts Positively to Above-Market Offer From Venture-Funded Company (Aug 2)

    • July 2017

  • Decision Diagnostics Corp. Receives Surprise Acquisition Offer from Valued Venture Funded Company (Jul 13)

    • May 2017

  • Decision Diagnostics Chairman and Director Robert Jagunich Retires from DECN Board of Directors (May 31)

  • DECN Subsidiaries File Amended Complaint Against Jonhson & Johnson Alleging Infringement Under Authoritative Doctrine of Equivalents (May 4)

    • March 2017

  • DECN Wins Opening Round in Innovatory Patent Infringement Suit Against Industry Goliath Johnson & Johnson (Mar 21)

  • DECN Victorious as U.S. Supreme Court Rejects Johnson & Johnson Appeal Ending 65 Month Patent Infringement Litigation (Mar 1)


    • (Return to Top)

    2016

    December 2016

  • DECN Increases Manufacturing Capacity, Opens International Markets for Popular GenUltimate! (Dec 1)

    • November 2016

  • DECN Opens International Markets for Popular Genultimate!, Increases Factory Capacity (Nov 30)

    • August 2016

  • DECN Litigation Victory Against Johnson + Johnson, Launches Foothold in On-Line Retail Markets for Its Popular "Gen" Products (Aug 23)

    • July 2016

  • Decision Diagnostics Ends Plans and Communications With Tauriga Sciences, Inc. Concerning Possible Reverse Merger Transaction (Jul 1)

    • June 2016

  • Decision Diagnostics Emerges Victorious in End to Acrimonious Patent Litigation With Divisions of Johnson + Johnson (Jun 2)

    • May 2016

  • Decision Diagnostics Nears Positive Ending of Its California Patent and Trademark Infringement Litigation With Divisions of Johnson + Johnson (May 12)

  • Download Available: Federal Circuit Court Order Denying Appeal made by Lifescan and Johnson & Johnson and imposing mandate on May 17, 2016

  • Download Available: Schedule Report for GenStrip50 TV Advertising (May 1)

    • April 2016

  • Download Available: Schedule Report for GenStrip50 TV Advertising (Apr 25)

  • Forbes Article: David-Goliath Fight Over Glucose Tests For Diabetics Hits Boiling Point (Apr 20)

  • Decision Diagnostics Engages Retail Monster LLC to Procure Big Box Retailers for Company's GenUltimate Product (Apr 14)

    • March 2016

  • Decision Diagnostics and Subsidiaries Elaborate on the Patent Infringement Lawsuit Against Johnson & Johnson and Two of Its Divisions (Mar 16)

  • DECN Subsidiaries Sue Johnson & Johnson and Several Divisions for Patent Infringement (Mar 14)

    • February 2016

  • Decision Diagnostics Conveys Opportunities and Potential Following Landmark Circuit Court Ruling Against Diabetes Testing Division of Johnson & Johnson (Feb 9)

    • January 2016

  • DECN Assesses Its Recent Landmark Legal Victories Over Diabetes Division Of Johnson & Johnson (Jan 28)

  • Decision Diagnostics Wins Federal Appeals Court Victory, Ruling Affirms J&J Division's Loss of US Patent No. 7,250,105 (Jan 21)

  • We Win! United States Court of Appeals for the Federal Circuit - Opinion Filed for LifeScan Scotland, Ltd. v. Pharmatech Solutions, Inc. (Jan 20)


    • (Return to Top)

    2015

    December 2015

  • Download Available: United States Court of Appeals for the Federal Circuit - Oral Argument Recording for LifeScan Scotland, Ltd. v. Pharmatech Solutions, Inc. (Dec 18)

    • June 2015

  • Decision Diagnostics Completes Investment in Korean R+D and Contract Manufacturing Partner (Jun 15)

  • Decision Diagnostics Executes Broad Manufacturing and R+D Agreement With Korean Manufacturer (Jun 4)

    • May 2015

  • Decision Diagnostics States Johnson & Johnson Division Offers Partial Surrender in Long Running Patent Battle (May 19)

  • Decision Diagnostics Files Application for Uplisting to OTCMarkets OTCQX (May 12)

    • April 2015

  • Decision Diagnostics Shrugs Off New Attack As Johnson & Johnson Panics In Patent Case (Apr 21)

  • U.S. Solicitor General Intervenes Against Johnson & Johnson in DECN's Long Running Patent Battle Over GenStrip 50 (Apr 14)

    • March 2015

  • Johnson & Johnson Division Attempts Final Appeal in Effort to Overturn Multiple USPTO Decisions Issued in DECN's Favor (Mar 31)

  • Decision Diagnostics Rejects Settlement Offers From J&J/Lifescan, Company's Prosecutions of Court Bond and Anti-Trust Actions Now Move On (Mar 4)

    • January 2015

  • Updated TV Commercial Fulfillment (Jan 20)

  • DECN Plans New Legal Challenge After LifeScan (J&J) Admits to Using Sworn Testimony From Expert With Falsified Credentials (Jan 14)


    • (Return to Top)

    2014

    December 2014

  • DECN Initiates End Game Strategy For Litigation With Division Of Johnson & Johnson (Dec 3)

    • November 2014

  • DECN's Subsidiary Initiates First In Industry Social Media Marketing Campaign For Genstrip50 (Nov 5)

    • August 2014

  • David Defeats Goliath (Again), DECN and Pharma Tech Solutions Awarded Victory Over Johnson & Johnson Lifescan in USPTO Final Ruling (Aug 11)

  • David Beats Goliath in Patent Rematch (Aug 7)

    • June 2014

  • DECN's Pharma Tech Subsidiary Places Significant Order for 50,000 Units of Genstrip 50 for Immediate Delivery to Select U.S. and International Distributors (Jun 3)

    • May 2014

  • Decision Diagnostics Corp. Subsidiary Pharma Tech Enters International Markets With Conformité Européenne (CE) Mark Submission (May 29)

  • GenStrip Opportunity Expands Under Full Control of DECN's PharmaTech Division (May 1)

    • April 2014

  • Decision Diagnostics Responds to Shasta Technologies FDA Safety Warning Letter (Apr 30)

  • Decision Diagnostics Subsidiary Acquires GenStrip (Apr 16)

    • March 2014

  • Decision Diagnostics Announces Posting and Airing of Its New GenStrip Commercial Titled "Monolith"(Mar 31)

  • Decision Diagnostics Announces Engagement of Mark Krakauer to Head Up Genstrip Private Label Sales Efforts (Mar 11)

  • TV Commercials Fulfillment #3 (Mar 4)

    • February 2014

  • TV Commercials Fulfillment #2 (Feb 26)

  • Decision Diagnostics Announces Agreement for Funding of Its Prosecution of Anti-Trust and False Advertising Suits Against Division of Johnson & Johnson (Feb 18)

  • TV Commercials Fulfillment #1 (Feb 15)

  • Decision Diagnostics Announces Agreement for the Funding of Its Prosecution of Anti-Trust and False Advertising Suits Against Division of Johnson & Johnson (Feb 14)

    • January 2014

  • Decision Diagnostics Announces Posting and Airing of Its New GenStrip Commercial Titled "A Winter Patchwork" (Jan 15)


    • (Return to Top)

    2013

    December 2013

  • Decision Diagnostics Closes $12.5 Million (Non-Dilutive) Credit Facility With Division of Platinum Credit Management (Dec 19)

  • Decision Diagnostics Starts its Turnaround (Dec 17)

  • Decision Diagnostics Receives Mandate From U.S. Court of Appeals for the Federal Circuit in the Long Running Dispute With J&J Division (Dec 17)

  • Mandate from Federal Appeals Court (.pdf) (Dec 11)

  • Decision Diagnostics' Board Votes to Uplist to OTC QX (Dec 10)

    • November 2013

  • Decision Diagnostics Takes Victory In Major Case Ruling (Nov 11)

  • Diabetes: J&J loses a round in glucose testing battle with Shasta (Nov 7)

  • Decision Diagnostics On Track For Growth And Increased Revenues (Nov 7)

  • DECN And Pharma Tech Solutions Receive Anticipated Ruling From The U.S. Federal Circuit Court Of Appeals, Reversing A Ruling By Lower Court Judge (Nov 5)

  • DECN Wins Only Case That Matters in Federal Circuit Court (.pdf) (Nov 4)

    • October 2013

  • Well Ahead Of Schedule, Decision Diagnostic's Pharma Tech Division Completes First Major Shipments Of Its Popular Genstrip Test Strip (Oct 31)

  • Decision Diagnostics Receives Signed Term Sheet Agreement For $12.5 Million Revolving Credit Facility Which Will Complete DECN’s GenStrip Roll-Out Plan (Oct 29)

  • Decision Diagnostics Could Be The New Vringo (Oct 24)

  • Recognized Healthcare And Financial Publications Acknowledge Decision Diagnostics’ GenStrip Market Potential (Oct 22)

  • DECN Set To Climb As GenStrip Enters Blood Glucose Monitoring Market With First Shipments (Oct 22)

  • Decision Diagnostic Blood Glucose Test Strip Technology Enters Market with Genstrip (Oct 22)

  • Court Ruling for Decision Diagnostics Order Staying Proceedings (.pdf) (Oct 9)

  • Decision Diagnostics' Pharma Tech Division Schedules Shipments For Its Popular GenStrip Test Strip (Oct 3)

  • Decision Diagnostics' Pharma Tech Division Schedules Large Order Shipments for Its Popular GenStrip Test Strip (Oct 1)

    • September 2013

  • David And Goliath Case Offers A Surprising Opportunity (Sep 26)

  • J&J feels Decision Diagnostics' sting in glucose strip patent fight (Sep 12)

  • J&J's Blood Sugar Testing Patent Spat Turns Sour (Sep 12)

  • J&J Seeks Court Aid To Protect Its Glucose Monitoring Test (Sep 11)

  • Decision Diagnostics Corp. Announces Completion and Airing of Its New Genstrip Video Titled "A Patchwork of Life" (Sep 10)

  • Decision Diagnostic's GenStrip Could Change the Blood Glucose Market (Sep 1)

    • August 2013

  • Court's Ruling on PharmaTech's Motion for Contempt (Aug 28)

  • GenStrip™ and USPTO Ruling (Aug 15)

  • Decision Diagnostics Subsidiary Makes Move and Sues Two Johnson and Johnson Divisions for False Advertising in Ongoing Battle (Aug 1)

    • May 2013

  • DECN Steps Into Role of White Knight by Offering Strategic Version of GenStrip™ Exclusively for Medicare Competitive Bidding Program (May 29)

  • Decision Diagnostics Corp. is saddened to announce the sudden passing of our long-time friend and Computer and Information Systems Manager, Mr. Alan B Binder (May 10)

    • April 2013

  • Decision Diagnostics Corp. and Its Subsidary PharmaTech Solutions Seek to End Pharma Giant's Alleged Restraint of Trade Tactics (Apr 5)

  • Decision Diagnostics Corp. and Its Subsidiary PharmaTech Solutions, Inc. Sue Johnson & Johnson Division LifeScan, Inc. and LifeScan Scotland Ltd. for Antitrust Violations (Apr 4)

    • March 2013

  • J&J Faces Potentially Disrupting Competition In Its Lucrative Glucose Monitoring Business From Tiny Diagnostics Outfit (Mar 11)

    • January 2013

  • FDA Review - Decision Summary (Jan 2)

  • FDA 510(k) Premarket Notification (Jan 2)


    • (Return to Top)

    2012

    December 2012

  • FDA 510(K) Clearance Letter (Dec 5)

  • Opportunity and Market for Decision Diagnostics (OTCBB:DECN) Shasta GenStrip®; at home diagnostic for testing blood glucose (Dec 4)

    • November 2012

  • Medical Technology Stock Q&A with Decision Diagnostics (Nov 28)

  • Medical Technology Stock Decision Diagnostics Lead Product Shasta Genstrip Positions for at-home testing of Blood Glucose Market (Nov 21)

  • Decision Diagnostics Set to Become Force in at-home testing of blood glucose, estimated $22.5 Billion Worldwide (Nov 16)

    • January 2012

  • Decision Diagnostics Corp. is saddened to announce the passing of our friend and financial guidance advisor, Mr. William N. Walling, Jr. (Jan 18)

  • Medical IT and Diagnostic Product Company Decision Diagnostics Announces Patent Enforcement Strategy for Their Smart Phone Based EMR Technology (Jan 11)


    • (Return to Top)

    2011

    December 2011

  • Decision Diagnostic Corp. Clarifies 10% Stock Dividend, Announces Patent Enforcement Strategy (Dec 27)

  • Decision Diagnostic Corp. (Formerly InstaCare) Announces 10% Stock Dividend (Dec 6)

  • Instacare Changes Name to Decision Diagnostics Corp.; Will Apply for Nasdaq Bx Exchange Listing (Dec 1)

    • May 2011

  • Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate (May 11)

  • InstaCare Corp. Receives Second Confidential Merger Offer From NASDAQ Traded Company (May 9)

    • April 2011

  • InstaCare Subsidiary Signs New Agreement for Expanded Management and Sales of Shasta Genstrip Into the $20 Billion Worldwide Diabetes Testing Market (Apr 18)

    • March 2011

  • Download AvailableHudson Securities - OTC Bulletin Board (.pdf) (Mar 11)

  • [email protected] coming soon!

  • InstaCare Announces Ready for Market [email protected] Mobile Health Media System for Pharmaceutical e-Detailing (Mar 10)

  • InstaCare Extends [email protected] & [email protected] Mobile EMR/EHR Technology to Smart Pad Systems (Mar 3)

  • InstaCare Announces Receipt of Technology and Patent Value Analysis Penned by Joseph Wolf, Ph.D and William Walling, CFA (Mar 2)

    • February 2011

  • InstaCare Files Full Utility Patent for [email protected] & [email protected] Technologies (Feb 28)


    • (Return to Top)

    2010

    June 2010

  • InstaCare Subsidiary Inks 5-Year Exclusive Pact for Distribution of Proprietary Diabetes Test Strip Into $9.8 Billion Testing Market (Jun 24)

  • InstaCare Retains Martin E. Janis & Company, Inc. to Launch Nationwide Comprehensive IR/PR Program(Jun 3)

    • March 2010

  • Instacare Corp. Files Patent Application for its [email protected] Cell Phone Centric Technologies (Mar 2)

    • February 2010

  • instaCare Corp. Announces Launch of Infomercial Marketing Strategy (Feb 2)

    • January 2010

  • Download Available: Instacare Corp. States Conference Call on January 27 is a Success - Click here to download Conference Call (.mp3) (Jan 27)

  • Instacare Corp. Announces Details of Conference Call on January 27 (Jan 25)

  • instaCare Corp. Finalizes [email protected] Parallel Marketing Strategy (Jan 25)

  • DownLoad Available: Download Chairman's Letter to Stockholders(.pdf) (Jan 20)

  • instaCare Corp. Elects William Lyons to Its Board of Directors (Jan 14)

  • instaCare Corp. Finalizes [email protected] Parallel Marketing Strategy (Jan 12)

  • Instacare Corp. to Host Shareholder Conference Call on January 27, 2010 to Discuss Recent Events (Jan 4)


    • (Return to Top)

    2009

    December 2009

  • Instacare Corp. Board of Directors Sets Growth Plans for 2010 (Dec 17)

  • Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary [email protected] Cell-Centric Products (Dec 3)

    • November 2009

  • instaCare in Renewal and Increase of its $2 Million Monthly Revolving Credit Facility With Centurion Credit Resources, LLC (Nov 30)

  • ISCR Becomes Instant Player in the Obamacare EMR/Cost Savings Sweepstakes (Nov 23)

  • instaCare Corp. Continues Turnaround, Reports 58% Revenues Increase for First Three Quarters (Nov 18)


    • (Return to Top)

    2008-2005

    May 2008

  • InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 (May 21)

    • September 2007

  • InstaCare Corp. Reviewing M&A Plans (Sep 26)

    • April 2007

  • Instacare Corp. Announces Expanded Product Lines, Group Vendor Agreements and Enhanced Customer Base (Apr 04)

    • July 2006

  • InstaCare Corp. in Contract Deliberations With Mexican Government Health Institute ISSSTE for E-Health Implementation Pact (Jul 20)

  • InstaCare Receives Enhanced Targets and Rating From Wasserman Morris in Latest Research Report (Jul 17)

    • May 2006

  • instaCare Corp. to Hold Conference Call May 25, 2006 (May 23)

    • September 2005

  • instaCare Corp. Comments on Recent Significant News Concerning the Efficacy of Cost Saving Wireless Technologies in Healthcare (Sep 13)


    • (Return to Top)